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ince the early 1980s, many investigators have
attempted to evaluate the quality of care pro-
vided by different types of health plans. The goal
of this research is to identify organizational forms
that offer quality advantages to patients (and indi-
viduals who might someday become patients). In
these studies, it has been particularly common to
compare managed care organizations (MCOs) to
fee-for-service (FFS) medicine [1–3].
As the health care system has evolved, however,
the meaning of these comparisons has changed for
two important reasons: (1) the distinction between
MCO and FFS has decreased, and (2) strong evi-
dence has accrued that patient groups within various
health plans are different in clinically significant
ways [4]. Interest has also developed in comparing
health plans within type, that is, comparing MCOs
to each other or one FFS plan to another, especially
for chronic diseases [5–7]. For these reasons, a new
form of statewide data collection is needed—the
creation of registries of patients with chronic dis-
eases. To permit meaningful measurement of quality
of care, these databases should include information
about the clinical severity of each patient’s condi-
tion and about the identity of the health plan and
medical group responsible for his or her care. Such
initiatives will be crucial to improving our ability to
assess the quality of care provided by health plans.
In the 1970s and early 1980s, MCOs primarily
consisted of group and staff model health mainte-
nance organizations (HMOs). Likewise, FFS was
essentially limited in most locations to solo or
small group clinicians practicing with relatively
little interference from health plans in clinical deci-
sion-making. More recently, however, “managed
care” has come to include a wide variety of orga-
nizations, from the traditional staff model HMO
to loosely affiliated network model HMOs and
even provider-sponsored organizations. Further-
more, very few FFS providers are truly free from
management of their care—they may have to ob-
tain preauthorization for procedures, prescribe
from a limited formulary, report compliance with
guidelines written by health plans, or in other
ways respond to health plans that want to modify
FFS provider behavior. In this context, the distinc-
tions between FFS and MCO may be difficult to
pinpoint. Furthermore, since each FFS and MCO
plan is different and some FFS are similar to some
MCOs, comparing all FFS to all MCOs in a state
may not be appropriate. In the current environ-
ment, there is a need to relate specific characteris-
tics of health plans (such as the financial incen-
tives for productivity and quality they offer to
providers, how aggressively they practice case
management, the quality of their information sys-
tems, etc.) to processes and outcomes of care [4].
Unfortunately, understanding the management
characteristics of health plans and medical groups
is necessary but not sufficient to permit meaning-
ful comparison of quality of care. Since the first
Medicare HMO demonstration projects, it has
been clear that health plans of different types en-
roll populations that are different in clinically im-
portant ways [8]. These differences in enrollment,
or “risk selection,” have persisted into the 1990s
[9] and are a major concern of individuals inter-
ested in payment to health plans. They should also
be carefully considered when making quality com-
parisons. For example, comparing the number of
hospitalizations for short-term complications of
diabetes per 1000 enrollees among MCO patients
versus FFS patients [3] can be biased by risk selec-
tion in two important ways: (1) MCOs could have
a lower (or higher) percentage of diabetics among
their overall population than FFS plans, and (2)
MCOs could selectively enroll, among all diabet-
ics, patients with less (or more) severe diabetes.
Thus, optimal quality measurement cannot occur
without good data about the clinical characteris-
tics of enrolled populations.
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Since private health insurance and Medicaid are
regulated primarily at the state level, improve-
ments in data collection to support assessment of
quality of care is also likely to come from individ-
ual states. Unfortunately, most states have long
focused health care monitoring efforts only on
hospitalization data. Many states require that hos-
pitals provide discharge abstracts—usually includ-
ing patient demographics, diagnoses, and proce-
dures, and sometimes a designation of the type of
health insurance billed for the hospitalization—to
a central state database. Some states have begun
to use these data to report hospital-specific quality
of care [10]. Hospitalization data, however, have
important limitations for the purposes of measur-
ing quality of care. They may provide the numera-
tor for the quality indicator (QI) “hospitalizations
for short-term complications of diabetes per 1000
enrolled patients.” On the other hand, since most
diabetics will not be hospitalized in a given year,
discharge databases help little in determining the
denominator of that QI. Limitations of this type ap-
ply to evaluation of any chronic disease using hospi-
talization information, and since few state hospital
discharge reports include the name of the health
plan (as opposed to the type of plan—MCO or
HMO versus FFS), the data that are collected are
minimally useful for comparison of specific plans
to each other, even for the quality of hospital care.
To adequately compare health plans, one must
understand the patient populations enrolled in
each plan and have access to process and out-
comes data. Enrollee data should include both the
number of patients with the condition of interest
and the clinical descriptors necessary to assess the
severity of the disease for individuals or the popu-
lation. It is probably unrealistic to expect that
health plan and medical group variables of inter-
est could be included in state databases (since
health care organizations may not want to share
management decisions). If each patient’s health
plan and medical group are identified in the data-
base, however, researchers could collect informa-
tion about organizational structure, provider fi-
nancial incentives, etc., in confidential surveys and
link these data to patients.
Disease-specific process measures and outcome
information are needed to allow comparison of
quality of care. Some additional data collection
would be required, but outcome measurement
could be achieved primarily by re-organization of
data already collected rather than new data acqui-
sition. Continuing with the diabetes example, a
state diabetes registry could be linked to hospital-
ization data available in most states to measure
admissions for short-term complications and many
other diabetes complications (e.g., limb amputa-
tions, cellulitis, myocardial infarction, and renal
failure). Linking the disease registries with national
vital statistics would allow mortality measurement.
If 23-hour admissions, outpatient surgical facility
utilization, and emergency room data are added to
routinely collected hospitalization data, as some
states are considering, researchers could measure
most acute and many long-term complications for
numerous diseases. Data about disease-specific pro-
cess measures as well (e.g., dates of ophthalmologic
exams for diabetics) could be reported to the reg-
istries by health plans or medical groups.
Although creation of such chronic disease regis-
tries might seem like a massive undertaking, there
are examples already in existence. The Surveillance,
Epidemiology, and End Results (SEER) registry col-
lects information about a several cancers. In addi-
tion to identifying numbers of patients with the dis-
ease, data collected include severity measures (stage
at diagnosis), process measures such as diagnostic
studies performed and therapeutic approaches used,
and outcomes measures including links to national
mortality statistics. This program has been in place
since 1973, includes data quality monitoring, has
supported a wide variety of clinical and health ser-
vices research [11–13], and has not violated patient
confidentiality despite covering approximately 14%
of the US population [14]. The SEER model could
be replicated for important chronic diseases such as
diabetes, congestive heart failure, and human im-
munodeficiency virus infection.
Limitations on data currently available to health
services researchers reduce the significance of com-
parisons of MCOs versus FFS, and the most valu-
able quality data for patients and purchasers would
be measurement of quality in specific plans of ei-
ther type. The creation of chronic disease registries
may provide the data necessary to advance re-
search about the relationship between health plan
characteristics and quality of care. The benefits of
this approach would extend beyond being a stimu-
lus to health services research. Particularly if public
reporting of plan comparisons were pursued, con-
sumers would have access to important informa-
tion about plan management for patients with
chronic illness to supplement measures that focus
more on preventive care (e.g., the Healthplan Em-
ployer Data and Information Set, or HEDIS) and pa-
tient satisfaction data. Purchasers would also benefit
from the ability to monitor the performance of
their health contractors. These benefits are likely
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to outweigh the cost of data collection, and the
SEER experience suggests the threat to patient
confidentiality is not insurmountable. Until avail-
able administrative data are improved, we are un-
likely to be able to significantly improve our abil-
ity to compare types of health plans or even one
health plan to another.
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